Hello,
I looked at this paper published in "The New England Journal of Medicine on 31.05.2023 with regards to Capivasertib.
https://www.nejm.org/doi/10.1056/NEJMoa2214131
1.
In general Capivasertib is AKT inhibitor for patients with AKT pathway–altered (PIK3CA, AKT1, or PTEN) tumors. It's given with Fulverstrant.
2.
The basis for RCT was as follows:
“In a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy”
3.
"The main aim was PFS assessed both in the overall population and among patients with AKT pathway–altered (PIK3CA, AKT1, or PTEN) tumors".
4.
Results:
AKT pathway alterted:
Median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group.
Overall population:
7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group
5.
I read it few time and can't see the results for nonaltered AKT patients.
It looks as the RCT had either altered or overall.
But Overall gives no indication whatsoever how did the nonlatered AKT group of patients responded to therapy.
It's like saying overall 5 years survival of breast cancer is 91%.
6.
I looked then into Supplementary Appendix S1 to get the idea of the results for non altered population.
My take is as follows:
- There were 400 patients in non altered group (split 50-50 in the RCT arms)
- Figure S2 had these as: Investigator-assessed progression-free survival:
- A) patients with AKT pathway non-altered tumors including unknown NGS result (per protocol)
-- Median PFS 7.2 vs 3.7
- B) patients with AKT pathway non-altered tumors excluding unknown NGS result (exploratory analysis)
-- Median PFS 5.3 vs 3.7
- C) only patients with unknown NGS result (post-hoc exploratory analysis)
-- Median PFS 10 vs 1.9.
Based on this In my it is clear that apivasertib–fulvestrant offer similar or even better PFS in certain nonaltered group than in the altrered group but I don't see this being routinely given?
I certainly did not hear oncologists in UK nor in Poland mentioning it as an option?
Any thoughts? Are you on this or were and if so which line of your treatment it was?
7.
Figure 3 of supplementary appendix.
Investigator-assessed progression-free survival by subgroup in patients with AKT pathway-altered tumors.
It looks as pre-monpausal patients, of Latin America, Eastern Europe, Russia, with prior CDK exposure and chemotherapy had closer or worse results that the placebo arm.
8.
I do not see same comparison for non-altered groups.
I would have thought this is equally important and surely could impact of oncologist chose of treatment?